ko	pathway	ratio_in_study	ratio_in_pop	p_value
ko05033	Nicotine addiction	15/169	56/7206	1.35140106749e-12
ko04728	Dopaminergic synapse	20/169	185/7206	9.18096467925e-09
ko04724	Glutamatergic synapse	18/169	152/7206	1.26387326143e-08
ko04721	Synaptic vesicle cycle	13/169	80/7206	3.29469284595e-08
ko05014	Amyotrophic lateral sclerosis (ALS)	12/169	74/7206	1.1643135321e-07
ko04080	Neuroactive ligand-receptor interaction	29/169	423/7206	1.30013550962e-07
ko05031	Amphetamine addiction	12/169	91/7206	1.18463323246e-06
ko04723	Retrograde endocannabinoid signaling	15/169	175/7206	1.34485730104e-05
ko05030	Cocaine addiction	9/169	73/7206	4.64401122173e-05
ko04514	Cell adhesion molecules (CAMs)	12/169	130/7206	4.89843802017e-05
ko04713	Circadian entrainment	11/169	136/7206	0.000328942584543
ko04024	cAMP signaling pathway	16/169	279/7206	0.000807521013901
ko04360	Axon guidance	14/169	233/7206	0.0010994477924
ko04010	MAPK signaling pathway	16/169	321/7206	0.00384017279457
ko04727	GABAergic synapse	8/169	110/7206	0.00417356035036
ko04720	Long-term potentiation	7/169	99/7206	0.00841123243838
ko04911	Insulin secretion	7/169	117/7206	0.0197819968883
ko05203	Viral carcinogenesis	1/169	277/7206	0.0227657146991
ko04930	Type II diabetes mellitus	4/169	54/7206	0.037248868063
ko00604	Glycosphingolipid biosynthesis - ganglio series	2/169	14/7206	0.0413605118403
ko04726	Serotonergic synapse	7/169	137/7206	0.0417840108024
ko05032	Morphine addiction	6/169	110/7206	0.0441808001829